Compound having PD-L1 expression-suppressing action
US11591297B2 · kind B2 · utility
0Cited by
0References
20Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Apr 8, 2020 |
| Grant date | Feb 28, 2023 |
| Priority date | — |
| Expiry date | Apr 8, 2040 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K2039/55511
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides a compound of formula (I): or a pharmaceutically acceptable salt thereof, wherein R1, R2, m and n are as defined in the specification, with an inhibitory effect of PD-L1 expression and an inhibitory effect of reduced production of IL-2 and a medicament useful for the treatment of a disease associated with the reduced immune function caused by the formation of PD-1/PD-L1 binding.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.